Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Navigate Social Media Safely Following Loss Of Facebook Protection

This article was originally published in The Tan Sheet

Executive Summary

Several drug companies may have shuttered their Facebook pages prematurely in August after the social networking site revoked their exclusive privilege to block consumer comments on their walls.

You may also be interested in...



In Brief: Okla. Plan B restriction blocked; CRN knocks disease claims via NAD; Facebook testimonial stings Vibrant Life

Oklahoma judge blocks Plan B restrictions; CRN challenges disease claims via NAD; Lonza backs Alomune claims, ERSP says; Facebook testimonial prompts Vibrant Life warning; Rx adulterant recalls, alerts; and Codex adopts 11 nutrient reference values;.

In Brief: Okla. Plan B restriction blocked; CRN knocks disease claims via NAD; Facebook testimonial stings Vibrant Life

Oklahoma judge blocks Plan B restrictions; CRN challenges disease claims via NAD; Lonza backs Alomune claims, ERSP says; Facebook testimonial prompts Vibrant Life warning; Rx adulterant recalls, alerts; and Codex adopts 11 nutrient reference values;.

FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era

Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel